Cancer therapeutics: Targeting the dark side of Myc

European Journal of Cancer

Volumn 41, Issue 16, 2005, Pages 2485-2501

  Ponzielli, Romina ^a   Katz, Sigal ^a   Barsyte Lovejoy, Dalia ^a   Penn, Linda Z ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antisense oligonucleotides; Cancer; ChIP chip; Deregulation; Max; Myc; Protein protein interactors; siRNA; Target genes; Therapeutics; Transformation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 4126; CISPLATIN; COMPLEMENTARY DNA; DAUNORUBICIN; INX 6295; MAX PROTEIN; MORPHOLINE DERIVATIVE; MYC PROTEIN; PORPHYRIN DERIVATIVE; PROTEIN BCL 2; PSORALEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BREAST CARCINOMA; BURKITT LYMPHOMA; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CRYSTAL STRUCTURE; DNA BINDING; DRUG EFFICACY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LUNG CANCER; MELANOMA; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE;

EID: 27544456436     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.08.017     Document Type: Article

References (199)

1. L.A. Emens Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer Am J Ther 12 3 2005 243 253
2. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2 2005 172 187
3. A. Ocana, C.A. Rodriguez, and J.J. Cruz Integrating trastuzumab in the treatment of breast cancer. Current status and future trends Clin Transl Oncol 7 3 2005 99 100
4. C. Sawyers Targeted cancer therapy Nature 432 7015 2004 294 297
5. C.V. Dang c-Myc target genes involved in cell growth, apoptosis, and metabolism Mol Cell Biol 19 1 1999 1 11
6. E.V. Prochownik c-Myc as a therapeutic target in cancer Expert Rev Anticancer Ther 4 2 2004 289 302
7. M. Eilers, D. Picard, and K.R. Yamamoto Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells Nature 340 6228 1989 66 68
8. R. Heikkila, G. Schwab, and E. Wickstrom A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1 Nature 328 6129 1987 445 449
9. M.F. Roussel Key effectors of signal transduction and G1 progression Adv Cancer Res 74 1998 1 24
10. S. Adachi, A.J. Obaya, and Z. Han c-Myc is necessary for DNA damage-induced apoptosis in the G (2) phase of the cell cycle Mol Cell Biol 21 15 2001 4929 4937
11. S.K. Oster, C.S. Ho, and E.L. Soucie The myc oncogene: MarvelouslY Complex Adv Cancer Res 84 2002 81 154
12. M.D. Cole The myc oncogene: its role in transformation and differentiation Annu Rev Genet 20 1986 361 384
13. L.M. Boxer, and C.V. Dang Translocations involving c-myc and c-myc function Oncogene 20 40 2001 5595 5610
14. C.E. Nesbit, J.M. Tersak, and E.V. Prochownik MYC oncogenes and human neoplastic disease Oncogene 18 19 1999 3004 3016
15. M. Schwab MYCN in neuronal tumours Cancer Lett 204 2 2004 179 187
16. W.D. Thomas, A. Raif, and L. Hansford N-myc transcription molecule and oncoprotein Int J Biochem Cell Biol 36 5 2004 771 775
17. R. Wu, L. Lin, and D.G. Beer Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas Am J Pathol 162 5 2003 1603 1610
18. C.M. Blakely, L. Sintasath, and C.M. D'Cruz Developmental stage determines the effects of MYC in the mammary epithelium Development 132 5 2005 1147 1160
19. T.D. Donaldson, and R.J. Duronio Cancer cell biology: Myc wins the competition Curr Biol 14 11 2004 R425 R427
20. I. Flores, D.J. Murphy, and L.B. Swigart Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia Oncogene 23 35 2004 5923 5930
21. B. Hoffman, A. Amanullah, and M. Shafarenko The proto-oncogene c-myc in hematopoietic development and leukemogenesis Oncogene 21 21 2002 3414 3421
22. S. Mai, and J.F. Mushinski c-Myc-induced genomic instability J Environ Pathol Toxicol Oncol 22 3 2003 179 199
23. J.A. Nilsson, and J.L. Cleveland Myc pathways provoking cell suicide and cancer Oncogene 22 56 2003 9007 9021
24. S. Pelengaris, M. Khan, and G. Evan c-MYC- more than just a matter of life and death Nat Rev Cancer 2 10 2002 764 776
25. A. Ruddell, P. Mezquita, and K.A. Brandvold B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis Am J Pathol 163 6 2003 2233 2245
26. E.V. Schmidt The role of c-myc in regulation of translation initiation Oncogene 23 18 2004 3217 3221
27. J. Secombe, S.B. Pierce, and R.N. Eisenman Myc - a weapon of mass destruction Cell 117 2 2004 153 156
28. L. Soucek, and G. Evan Myc - is this the oncogene from Hell? Cancer Cell 1 5 2002 406 408
29. J.H. Patel, A.P. Loboda, and M.K. Showe Analysis of genomic targets reveals complex functions of MYC Nat Rev Cancer 4 7 2004 562 568
30. B. Luscher Function and regulation of the transcription factors of the Myc/Max/Mad network Gene 277 1-2 2001 1 14
31. C.V. Dang, C. Dolde, and M.L. Gillison Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins Proc Natl Acad Sci USA 89 2 1992 599 602
32. C. Grandori, S.M. Cowley, and L.P. James The Myc/Max/Mad network and the transcriptional control of cell behavior Annu Rev Cell Dev Biol 16 2000 653 699
33. S.D. Conzen, K. Gottlob, and E.S. Kandel Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc- transrepression correlates with acceleration of apoptosis Mol Cell Biol 20 16 2000 6008 6018
34. A. Herbst, M.T. Hemann, and K.A. Tworkowski A conserved element in Myc that negatively regulates its proapoptotic activity EMBO Rep 6 2 2005 177 183
35. M. Fladvad, K. Zhou, and A. Moshref N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding J Mol Biol 346 1 2005 175 189
36. I.J. McEwan, K. Dahlman-Wright, and J. Ford Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding Biochemistry 35 29 1996 9584 9593
37. E.M. Blackwood, and R.N. Eisenman Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science 251 4998 1991 1211 1217
38. S.K. Nair, and S.K. Burley X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors Cell 112 2 2003 193 205
39. P. Brownlie, T. Ceska, and M. Lamers The crystal structure of an intact human Max-DNA complex: new insights into mechanisms of transcriptional control Structure 5 4 1997 509 520
40. B. Amati, S.R. Frank, and D. Donjerkovic Function of the c-Myc oncoprotein in chromatin remodeling and transcription Biochim Biophys Acta 1471 3 2001 M135 M145
41. S.B. McMahon, H.A. Van Buskirk, and K.A. Dugan The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins Cell 94 3 1998 363 374
42. J. Park, S. Kunjibettu, and S.B. McMahon The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis Genes Dev 15 13 2001 1619 1624
43. P.A. Grant, D. Schieltz, and M.G. Pray-Grant The ATM-related cofactor Tra1 is a component of the purified SAGA complex Mol Cell 2 6 1998 863 867
44. S.B. McMahon, M.A. Wood, and M.D. Cole The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc Mol Cell Biol 20 2 2000 556 562
45. M. Fuchs, J. Gerber, and R. Drapkin The p400 complex is an essential E1A transformation target Cell 106 3 2001 297 307
46. J. Vervoorts, J.M. Luscher-Firzlaff, and S. Rottmann Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP EMBO Rep 4 5 2003 484 490
47. M.A. Wood, S.B. McMahon, and M.D. Cole An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc Mol Cell 5 2 2000 321 330
48. S.W. Cheng, K.P. Davies, and E. Yung c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function Nat Genet 22 1 1999 102 105
49. N. Sevenet, A. Lellouch-Tubiana, and D. Schofield Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations Hum Mol Genet 8 13 1999 2359 2368
50. N. Sevenet, E. Sheridan, and D. Amram Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers Am J Hum Genet 65 5 1999 1342 1348
51. I. Versteege, N. Sevenet, and J. Lange Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer Nature 394 6689 1998 203 206
52. J. Park, M.A. Wood, and M.D. Cole BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation Mol Cell Biol 22 5 2002 1307 1316
53. D. Sakamuro, K.J. Elliott, and R. Wechsler-Reya BIN1 is a novel MYC-interacting protein with features of a tumour suppressor Nat Genet 14 1 1996 69 77
54. D. Sakamuro, and G.C. Prendergast New Myc-interacting proteins: a second Myc network emerges Oncogene 18 19 1999 2942 2954
55. A. Pineda-Lucena, C.S. Ho, and D.Y. Mao A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants J Mol Biol 351 1 2005 182 194
56. M. Hirst, C. Ho, and L. Sabourin A two-hybrid system for transactivator bait proteins Proc Natl Acad Sci USA 98 15 2001 8726 8731
57. A. Huang, C.S. Ho, and R. Ponzielli Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells Cancer Res 65 13 2005 5607 5619
58. R.C. Osthus, B. Karim, and J.E. Prescott The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumours and has limited transforming activity in vivo Cancer Res 65 13 2005 5620 5627
59. J.E. Prescott, R.C. Osthus, and L.A. Lee A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation J Biol Chem 276 51 2001 48276 48284
60. Y.C. Broder, S. Katz, and A. Aronheim The ras recruitment system, a novel approach to the study of protein-protein interactions Curr Biol 8 20 1998 1121 1124
61. H. Hennemann, L. Vassen, and C. Geisen Identification of a novel Kruppel-associated box domain protein, Krim-1, that interacts with c-Myc and inhibits its oncogenic activity J Biol Chem 278 31 2003 28799 28811
62. A. Datta, A. Nag, and W. Pan Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc J Biol Chem 279 35 2004 36698 36707
63. Y. Qi, M.A. Gregory, and Z. Li p19ARF directly and differentially controls the functions of c-Myc independently of p53 Nature 431 7009 2004 712 717
64. K.P. Smith, M. Byron, and B.C. O'Connell c-Myc localisation within the nucleus: evidence for association with the PML nuclear body J Cell Biochem 93 6 2004 1282 1296
65. S. Cairo, F. De Falco, and M. Pizzo PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts Oncogene 24 13 2005 2195 2203
66. R.W. Ching, G. Dellaire, and C.H. Eskiw PML bodies: a meeting place for genomic loci? J Cell Sci 118 Pt 5 2005 847 854
67. M. Yu, S. Schreek, and C. Cerni PARP-10, a novel Myc-interacting protein with poly (ADP-ribose) polymerase activity, inhibits transformation Oncogene 24 12 2005 1982 1993
68. T. Veldman, X. Liu, and H. Yuan Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter Proc Natl Acad Sci USA 100 14 2003 8211 8216
69. S.E. Salghetti, A.A. Caudy, and J.G. Chenoweth Regulation of transcriptional activation domain function by ubiquitin Science 293 5535 2001 1651 1653
70. S.E. Salghetti, S.Y. Kim, and W.P. Tansey Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilise Myc EMBO J 18 3 1999 717 726
71. S.Y. Kim, A. Herbst, and K.A. Tworkowski Skp2 regulates Myc protein stability and activity Mol Cell 11 5 2003 1177 1188
72. N. von der Lehr, S. Johansson, and S. Wu The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription Mol Cell 11 5 2003 1189 1200
73. M. Gstaiger, R. Jordan, and M. Lim Skp2 is oncogenic and overexpressed in human cancers Proc Natl Acad Sci USA 98 9 2001 5043 5048
74. E. Latres, R. Chiarle, and B.A. Schulman Role of the F-box protein Skp2 in lymphomagenesis Proc Natl Acad Sci USA 98 5 2001 2515 2520
75. H. Huang, K.M. Regan, and F. Wang Skp2 inhibits FOXO1 in tumour suppression through ubiquitin-mediated degradation Proc Natl Acad Sci USA 102 5 2005 1649 1654
76. M.A. Gregory, Y. Qi, and S.R. Hann Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localisation J Biol Chem 278 51 2003 51606 51612
77. B. Lutterbach, and S.R. Hann Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis Mol Cell Biol 14 8 1994 5510 5522
78. R.C. Sears The life cycle of C-Myc - from synthesis to degradation Cell Cycle 3 9 2004 1133 1137
79. M.A. Gregory, and S.R. Hann c-Myc proteolysis by the ubiquitin-proteosome pathway: stabilisation of c-Myc in Burkitt's lymphoma cells Mol Cell Biol 20 7 2000 2423 2435
80. K. Bhatia, K. Huppi, and G. Spangler Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas Nat Genet 5 1 1993 56 61
81. M. Welcker, A. Orian, and J.A. Grim A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size Curr Biol 14 20 2004 1852 1857
82. M. Welcker, A. Orian, and J. Jin The Fbw7 tumour suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation Proc Natl Acad Sci USA 101 24 2004 9085 9090
83. M. Yada, S. Hatakeyama, and T. Kamura Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7 EMBO J 23 10 2004 2116 2125
84. R. Sears, G. Leone, and J. DeGregori Ras enhances Myc protein stability Mol Cell 3 2 1999 169 179
85. Q.M. Guo, R.L. Malek, and S. Kim Identification of c-myc responsive genes using rat cDNA microarray Cancer Res 60 21 2000 5922 5928
86. B.C. O'Connell, A.F. Cheung, and C.P. Simkevich A large scale genetic analysis of c-Myc-regulated gene expression patterns J Biol Chem 278 14 2003 12563 12573
87. J.D. Watson, S.K. Oster, and M. Shago Identifying genes regulated in a Myc-dependent manner J Biol Chem 277 40 2002 36921 36930
88. Q. Yu, M. He, and N.H. Lee Identification of Myc-mediated death response pathways by microarray analysis J Biol Chem 277 15 2002 13059 13066
89. P.C. Fernandez, S.R. Frank, and L. Wang Genomic targets of the human c-Myc protein Genes Dev 17 9 2003 1115 1129
90. Z. Li, S. Van Calcar, and C. Qu A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells Proc Natl Acad Sci USA 100 14 2003 8164 8169
91. D.Y. Mao, J.D. Watson, and P.S. Yan Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression Curr Biol 13 10 2003 882 886
92. T.K. Blackwell, J. Huang, and A. Ma Binding of myc proteins to canonical and noncanonical DNA sequences Mol Cell Biol 13 9 1993 5216 5224
93. A. Orian, B. van Steensel, and J. Delrow Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network Genes Dev 17 9 2003 1101 1114
94. T. Hulf, P. Bellosta, and M. Furrer Whole-genome analysis reveals a strong positional bias of conserved dMyc-dependent E-boxes Mol Cell Biol 25 9 2005 3401 3410
95. H. Izumi, C. Molander, and L.Z. Penn Mechanism for the transcriptional repression by c-Myc on PDGF β-receptor J Cell Sci 114 Pt. 8 2001 1533 1544
96. S.K. Oster, W.W. Marhin, and C. Asker Myc is an essential negative regulator of platelet-derived growth factor β receptor expression Mol Cell Biol 20 18 2000 6768 6778
97. J. Seoane, H.V. Le, and J. Massague Myc suppression of the p21 (Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage Nature 419 6908 2002 729 734
98. P. Staller, K. Peukert, and A. Kiermaier Repression of p15INK4b expression by Myc through association with Miz-1 Nat Cell Biol 3 4 2001 392 399
99. S. Cawley, S. Bekiranov, and H.H. Ng Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs Cell 116 4 2004 499 509
100. K.A. O'Donnell, E.A. Wentzel, and K.I. Zeller c-Myc-regulated microRNAs modulate E2F1 expression Nature 435 7043 2005 839 843
101. L. He, J.M. Thomson, and M.T. Hemann A microRNA polycistron as a potential human oncogene Nature 435 7043 2005 828 833
102. The Myc Target Gene Database. 〈http://www.myc-cancer-gene.org/site/ mycTargetDB.asp〉.
103. K.I. Zeller, A.G. Jegga, and B.J. Aronow An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets Genome Biol 4 10 2003 R69
104. M.A. Nikiforov, S. Chandriani, and J. Park TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins Mol Cell Biol 22 14 2002 5054 5063
105. R.A. Greenberg, R.C. O'Hagan, and H. Deng Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation Oncogene 18 5 1999 1219 1226
106. M.A. Blasco, H.W. Lee, and M.P. Hande Telomere shortening and tumour formation by mouse cells lacking telomerase RNA Cell 91 1 1997 25 34
107. C. Bouchard, O. Dittrich, and A. Kiermaier Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter Genes Dev 15 16 2001 2042 2047
108. C. Bouchard, K. Thieke, and A. Maier Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 EMBO J 18 19 1999 5321 5333
109. H.A. Coller, C. Grandori, and P. Tamayo Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signalling, and adhesion Proc Natl Acad Sci USA 97 7 2000 3260 3265
110. H. Hermeking, C. Rago, and M. Schuhmacher Identification of CDK4 as a target of c-MYC Proc Natl Acad Sci USA 97 5 2000 2229 2234
111. S. Ezoe, I. Matsumura, and S. Nakata GATA-2/estrogen receptor chimera regulates cytokine-dependent growth of hematopoietic cells through accumulation of p21(WAF1) and p27(Kip1) proteins Blood 100 10 2002 3512 3520
112. R.C. O'Hagan, M. Ohh, and G. David Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression Genes Dev 14 17 2000 2185 2191
113. I. Perez-Roger, S.H. Kim, and B. Griffiths Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27 (Kip1) and p21 (Cip1 EMBO J 18 19 1999 5310 5320
114. K. Rothermund, K. Rogulski, and E. Fernandes C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions Cancer Res 65 6 2005 2097 2107
115. S.R. Eberhardy, and P.J. Farnham c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism J Biol Chem 276 51 2001 48562 48571
116. S.R. Eberhardy, and P.J. Farnham Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter J Biol Chem 277 42 2002 40156 40162
117. S. Kanazawa, L. Soucek, and G. Evan c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis Oncogene 22 36 2003 5707 5711
118. Z.A. Felton-Edkins, N.S. Kenneth, and T.R. Brown Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc Cell Cycle 2 3 2003 181 184
119. N. Gomez-Roman, C. Grandori, and R.N. Eisenman Direct activation of RNA polymerase III transcription by c-Myc Nature 421 6920 2003 290 294
120. I. Grummt Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus Genes Dev 17 14 2003 1691 1702
121. T. Moss At the crossroads of growth control; making ribosomal RNA Curr Opin Genet Dev 14 2 2004 210 217
122. A. Arabi, S. Wu, and K. Ridderstrale c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription Nat Cell Biol 7 3 2005 303 310
123. C. Grandori, N. Gomez-Roman, and Z.A. Felton-Edkins c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I Nat Cell Biol 7 3 2005 311 318
124. S.S. Grewal, L. Li, and A. Orian Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development Nat Cell Biol 7 3 2005 295 302
125. K. Peukert, P. Staller, and A. Schneider An alternative pathway for gene regulation by Myc EMBO J 16 18 1997 5672 5686
126. A.L. Roy, C. Carruthers, and T. Gutjahr Direct role for Myc in transcription initiation mediated by interactions with TFII-I Nature 365 6444 1993 359 361
127. C. Brenner, R. Deplus, and C. Didelot Myc represses transcription through recruitment of DNA methyltransferase corepressor EMBO J 24 2 2005 336 346
128. M. Austen, C. Cerni, and J.M. Luscher-Firzlaff YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc Oncogene 17 4 1998 511 520
129. A. Shrivastava, S. Saleque, and G.V. Kalpana Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc Science 262 5141 1993 1889 1892
130. D.Y. Mao, D. Barsyte-Lovejoy, and C.S. Ho Promoter-binding and repression of PDGFRB by c-Myc are separable activities Nucl Acids Res 32 11 2004 3462 3468
131. W.W. Marhin, S. Chen, and L.M. Facchini Myc represses the growth arrest gene gadd45 Oncogene 14 23 1997 2825 2834
132. D. Barsyte-Lovejoy, D.Y. Mao, and L.Z. Penn c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism Oncogene 23 19 2004 3481 3486
133. D.W. Felsher, and J.M. Bishop Reversible tumourigenesis by MYC in hematopoietic lineages Mol Cell 4 2 1999 199 207
134. C.M. D'Cruz, E.J. Gunther, and R.B. Boxer c-MYC induces mammary tumourigenesis by means of a preferred pathway involving spontaneous Kras2 mutations Nat Med 7 2 2001 235 239
135. C.M. Shachaf, A.M. Kopelman, and C. Arvanitis MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer Nature 431 7012 2004 1112 1117
136. I. Arnold, and F.M. Watt c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny Curr Biol 11 8 2001 558 568
137. S. Pelengaris, M. Khan, and G.I. Evan Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression Cell 109 3 2002 321 334
138. J. Jonkers, and A. Berns Oncogene addiction: sometimes a temporary slavery Cancer Cell 6 6 2004 535 538
139. F.E. Cotter Unraveling biologic therapy for Bcl-2-expressing malignancies Semin Oncol 31 6 Suppl 16 2004 18 21 discussion 33
140. S. Fulda, and K.M. Debatin Targeting apoptosis pathways in cancer therapy Curr Cancer Drug Targets 4 7 2004 569 576
141. I.M. Ghobrial, T.E. Witzig, and A.A. Adjei Targeting apoptosis pathways in cancer therapy CA Cancer J Clin 55 3 2005 178 194
142. S.M. Osford, C.L. Dallman, and P.W. Johnson Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells Curr Med Chem 11 8 2004 1031 1039
143. E.L. Wickstrom, T.A. Bacon, and A. Gonzalez Human promyelocytic leukaemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA Proc Natl Acad Sci USA 85 4 1988 1028 1032
144. P.S. Eder, R.J. DeVine, and J.M. Dagle Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma Antisense Res Dev 1 2 1991 141 151
145. S.T. Crooke Molecular mechanisms of action of antisense drugs Biochim Biophys Acta 1489 1 1999 31 44
146. E. Koller, W.A. Gaarde, and B.P. Monia Elucidating cell signalling mechanisms using antisense technology Trends Pharmacol Sci 21 4 2000 142 148
147. S.T. Crooke Molecular mechanisms of antisense drugs: RNase H Antisense Nucl Acid Drug Dev 8 2 1998 133 134
148. R.A. Stahel, and U. Zangemeister-Wittke Antisense oligonucleotides for cancer therapy - an overview Lung Cancer 41 Suppl. 1 2003 S81 S88
149. J.T. Holt, R.L. Redner, and A.W. Nienhuis An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation Mol Cell Biol 8 2 1988 963 973
150. E.V. Prochownik, J. Kukowska, and C. Rodgers c-myc Antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukaemia cells Mol Cell Biol 8 9 1988 3683 3695
151. J.S. Carroll, A. Swarbrick, and E.A. Musgrove Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens Cancer Res 62 11 2002 3126 3131
152. Y. Huang, R. Snyder, and M. Kligshteyn Prevention of tumour formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate Mol Med 1 6 1995 647 658
153. J.B. Smith, and E. Wickstrom Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumourigenesis in a murine B-cell lymphoma transplant model J Natl Cancer Inst 90 15 1998 1146 1154
154. J.B. Smith, and E. Wickstrom Inhibition of tumourigenesis in a murine B-cell lymphoma transplant model by c-Myc complementary oligonucleotides Adv Exp Med Biol 451 1998 17 22
155. G. Citro, I. D'Agnano, and C. Leonetti c-myc Antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice Cancer Res 58 2 1998 283 289
156. D.C. Knapp, J.E. Mata, and M.T. Reddy Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model Anticancer Drugs 14 1 2003 39 47
157. P.L. Iversen, V. Arora, and A.J. Acker Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans Clin Cancer Res 9 7 2003 2510 2519
158. G.R. Devi, T.M. Beer, and C.L. Corless In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumours Clin Cancer Res 11 10 2005 3930 3938
159. C. Leonetti, A. Biroccio, and B. Benassi Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoural efficacy in vivo in a human melanoma line Cancer Gene Ther 8 6 2001 459 468
160. G. Zupi, M. Scarsella, and S.C. Semple Antitumour efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence Clin Cancer Res 11 5 2005 1990 1998
161. D.A. Stewart, S.D. Thomas, and C.A. Mayfield Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation Nucl Acids Res 29 19 2001 4052 4061
162. D.A. Stewart, X. Xu, and S.D. Thomas Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumour progression Nucl Acids Res 30 11 2002 2565 2574
163. M. Pooga, T. Land, and T. Bartfai PNA oligomers as tools for specific modulation of gene expression Biomol Eng 17 6 2001 183 192
164. G. Cutrona, E.M. Carpaneto, and M. Ulivi Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localisation signal Nat Biotechnol 18 3 2000 300 303
165. G. Cutrona, E.M. Carpaneto, and A. Ponzanelli Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer Cancer Res 63 19 2003 6144 6148
166. A. Biroccio, B. Benassi, and S. Amodei c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells Mol Pharmacol 60 1 2001 174 182
167. R. Supino, P. Perego, and L. Gatti A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line Eur J Cancer 37 17 2001 2247 2256
168. J.R. Bertrand, M. Pottier, and A. Vekris Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo Biochem Biophys Res Commun 296 4 2002 1000 1004
169. Y.H. Wang, S. Liu, and G. Zhang Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumour cells growth in vitro and in vivo Breast Cancer Res 7 2 2005 R220 R228
170. E. Song, S.K. Lee, and J. Wang RNA interference targeting Fas protects mice from fulminant hepatitis Nat Med 9 3 2003 347 351
171. E. Song, P. Zhu, and S.K. Lee Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat Biotechnol 23 6 2005 709 717
172. T.R. Brummelkamp, R. Bernards, and R. Agami Stable suppression of tumourigenicity by virus-mediated RNA interference Cancer Cell 2 3 2002 243 247
173. E.M. McGuffie, and C.V. Catapano Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene Nucl Acids Res 30 12 2002 2701 2709
174. E.M. McGuffie, D. Pacheco, and G.M. Carbone Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukaemia cells Cancer Res 60 14 2000 3790 3799
175. G.M. Carbone, E. McGuffie, and S. Napoli DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene Nucl Acids Res 32 8 2004 2396 2410
176. C.L. Grand, H. Han, and R.M. Munoz The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumour growth in vivo Mol Cancer Ther 1 8 2002 565 573
177. T. Lemarteleur, D. Gomez, and R. Paterski Stabilisation of the c-myc gene promoter quadruplex by specific ligands' inhibitors of telomerase Biochem Biophys Res Commun 323 3 2004 802 808
178. J. Seenisamy, S. Bashyam, and V. Gokhale Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure J Am Chem Soc 127 9 2005 2944 2959
179. T. Simonsson, and M. Henriksson c-myc Suppression in Burkitt's lymphoma cells Biochem Biophys Res Commun 290 1 2002 11 15
180. L. Soucek, M. Helmer-Citterich, and A. Sacco Design and properties of a Myc derivative that efficiently homodimerises Oncogene 17 19 1998 2463 2472
181. L. Soucek, R. Jucker, and L. Panacchia Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis Cancer Res 62 12 2002 3507 3510
182. S. Pelengaris, T. Littlewood, and M. Khan Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion Mol Cell 3 5 1999 565 577
183. L. Soucek, S. Nasi, and G.I. Evan Omomyc expression in skin prevents Myc-induced papillomatosis Cell Death Differ 11 9 2004 1038 1045
184. F. Kohlhuber, H. Hermeking, and A. Graessmann Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts J Biol Chem 270 48 1995 28797 28805
185. L. Giorello, L. Clerico, and M.P. Pescarolo Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence Cancer Res 58 16 1998 3654 3659
186. E. Nieddu, A. Melchiori, and M.P. Pescarolo Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc FASEB J 19 6 2005 632 634
187. M.P. Pescarolo, L. Bagnasco, and D. Malacarne A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems FASEB J 15 1 2001 31 33
188. T. Berg, S.B. Cohen, and J. Desharnais Small-molecule antagonists of Myc/Max dimerisation inhibit Myc-induced transformation of chicken embryo fibroblasts Proc Natl Acad Sci USA 99 6 2002 3830 3835
189. X. Yin, C. Giap, and J.S. Lazo Low molecular weight inhibitors of Myc-Max interaction and function Oncogene 22 40 2003 6151 6159
190. Y. Guo, J.L. Cleveland, and T.G. O'Brien Haploinsufficiency for odc modifies mouse skin tumour susceptibility Cancer Res 65 4 2005 1146 1149
191. J.A. Nilsson, U.B. Keller, and T.A. Baudino Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumour formation Cancer Cell 7 5 2005 433 444
192. K.M. Desbiens, R.G. Deschesnes, and M.M. Labrie c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade Biochem J 372 Pt 2 2003 631 641
193. C. Iavarone, A. Catania, and M.J. Marinissen The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signalling pathway J Biol Chem 278 50 2003 50024 50030
194. E. Kerkhoff, R. Houben, and S. Loffler Regulation of c-myc expression by Ras/Raf signalling Oncogene 16 2 1998 211 216
195. R.J. Grumont, A. Strasser, and S. Gerondakis B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-κB regulated c-myc transcription Mol Cell 10 6 2002 1283 1294
196. R.S. Watnick, Y.N. Cheng, and A. Rangarajan Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumour angiogenesis Cancer Cell 3 3 2003 219 231
197. T.C. He, A.B. Sparks, and C. Rago Identification of c-MYC as a target of the APC pathway Science 281 5382 1998 1509 1512
198. N. Kiuchi, K. Nakajima, and M. Ichiba STAT3 is required for the gp 130-mediated full activation of the c-myc gene J Exp Med 189 1 1999 63 73
199. T. Oskarsson, and A. Trumpp The Myc trilogy: lord of RNA polymerases Nat Cell Biol 7 3 2005 215 217